Three-dimensional volumetric assessment and stability of simultaneously placed implant following sinus floor augmentation with deproteinized human demineralized tooth matrix or deproteinized bovine bone mineral: a randomized controlled clinical trial
Oral and Maxillofacial Surgery · 2024
DOI: 10.1007/s10006-024-01263-w ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Oral and Maxillofacial Surgery, 2024. Verfasst von Nattha Paetnukroh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Prince of Songkla University, Hat Yai, 90112, Songkhla, Thailand. Hauptthemen laut MEDLINE: Sinus Floor Augmentation, Cone-Beam Computed Tomography, Imaging, Three-Dimensional. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 56 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: This study aimed to analyze and compare three-dimensional volumetric bone changes and stability of simultaneously placed dental implants following sinus augmentation using deproteinized human demineralized tooth matrix (dpDTM) and deproteinized bovine bone mineral (DBBM). METHODS: Twenty-four patients who required lateral maxillary sinus floor augmentation with simultaneous dental implant placement were randomly assigned to receive either dpDTM (n = 12) or DBBM (n = 12). Cone-beam computed tomography and resonance frequency analysis of implant stability were conducted immediately after surgery and 6 months postoperatively. Changes in the graft sinus floor and graft height volumes in the sagittal and coronal views, along with the implant stability quotient (ISQ), were analyzed and compared. RESULTS: Volumetric graft alteration was comparable between dpDTM (120.33 ± 77.48 mm3) and DBBM (108.51 ± 65.15 mm3) (p = 0.690). Reduction in the average graft height was also comparable: dpDTM group ranged from - 0.59 to - 0.93 mm and the DBBM group ranged from - 0.55 to - 0.82 mm (p > 0.05) at most examined levels. However, greater reduction in the mesial-graft height occurred in the dpDTM group (- 1.08 ± 0.70 mm vs. -0.58 ± 0.39 mm, p = 0.04). The ISQ values increased similarly in both groups to reach 70 at 6 months. CONCLUSION: dpDTM demonstrated comparable stability in graft volume and height during the healing process compared to DBBM and could serve as a viable alternative to DBBM for sinus floor augmentation with simultaneous implant placement.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Prince of Songkla University, Hat Yai, 90112, Songkhla, Thailand.
- Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Prince of Songkla University, Hat Yai, 90112, Songkhla, Thailand. narit.l@psu.ac.th.
ORCID-Profile: Nattha Paetnukroh
Zitieren
APA
Paetnukroh, N., Leepong, N., & Suttapreyasri, S. (2024). Three-dimensional volumetric assessment and stability of simultaneously placed implant following sinus floor augmentation with deproteinized human demineralized tooth matrix or deproteinized bovine bone mineral: a randomized controlled clinical trial. Oral and Maxillofacial Surgery. https://doi.org/10.1007/s10006-024-01263-w
Vancouver
Paetnukroh N, Leepong N, Suttapreyasri S. Three-dimensional volumetric assessment and stability of simultaneously placed implant following sinus floor augmentation with deproteinized human demineralized tooth matrix or deproteinized bovine bone mineral: a randomized controlled clinical trial. Oral and Maxillofacial Surgery. 2024. doi:10.1007/s10006-024-01263-w
BibTeX
@article{Paetnukroh2024,
author = {Paetnukroh, Nattha and Leepong, Narit and Suttapreyasri, Srisurang},
title = {Three-dimensional volumetric assessment and stability of simultaneously placed implant following sinus floor augmentation with deproteinized human demineralized tooth matrix or deproteinized bovine bone mineral: a randomized controlled clinical trial},
journal = {Oral and Maxillofacial Surgery},
year = {2024},
doi = {10.1007/s10006-024-01263-w}
}
EUVIMED